Compare Goodyear Tire & Rubber Co (GT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Merck & Co., Inc. — how do they compare? Goodyear Tire & Rubber Co trades at $4.7 (market cap $1.37B), while Merck & Co., Inc. trades at $144.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 256.4× Goodyear Tire & Rubber Co's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Merck & Co., Inc. for 98 Days on average.
| GT | MRK | |
|---|---|---|
Market Cap | $1.37B | $351.28B |
Volume | 9,470,773 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $156.43 |
52-Week Low | $4.66 | $82.49 |
Typical Hold Time | 57 Days | 98 Days |
Enterprise Value | $8.72B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $4.69, up 0.64% on the day, but remains near 52-week lows amid a bearish technical outlook. The company reported a Q2 2026 loss of $0.61 per share, beating estimates but reflecting ongoing volume pressures. Revenue has declined from $20.8B in 2022 to $18.3B in 2025, with a net income margin of -14.37% in the latest period. Despite a low P/E of 4.69 and P/B of 0.48, negative ROE and ROA highlight profitability challenges. Recent news highlights a restructuring plan targeting margin improvement and debt reduction.
The outlook is mixed, with a consensus price target of $8.00 suggesting significant upside if restructuring succeeds. However, risks include persistent volume declines, high debt levels, and execution uncertainty. Analyst sentiment is cautious with 34.62% buy ratings, 50% hold, and 15.38% sell. Investors should weigh the deep value metrics against fundamental headwinds in the competitive tire industry.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
